MX355408B - Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. - Google Patents
Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.Info
- Publication number
- MX355408B MX355408B MX2014015643A MX2014015643A MX355408B MX 355408 B MX355408 B MX 355408B MX 2014015643 A MX2014015643 A MX 2014015643A MX 2014015643 A MX2014015643 A MX 2014015643A MX 355408 B MX355408 B MX 355408B
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotides
- chemically modified
- oligonucleotide
- locked nucleic
- nucleic acid
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 6
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 2
- 238000007385 chemical modification Methods 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662746P | 2012-06-21 | 2012-06-21 | |
| US201361801533P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047157 WO2013192576A2 (en) | 2012-06-21 | 2013-06-21 | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015643A MX2014015643A (es) | 2015-07-17 |
| MX355408B true MX355408B (es) | 2018-04-18 |
Family
ID=49769732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015643A MX355408B (es) | 2012-06-21 | 2013-06-21 | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9388408B2 (https=) |
| EP (2) | EP2864482A4 (https=) |
| JP (2) | JP6208228B2 (https=) |
| KR (1) | KR101928418B1 (https=) |
| CN (2) | CN107236735B (https=) |
| AU (1) | AU2013278011B2 (https=) |
| CA (1) | CA2876180C (https=) |
| DK (1) | DK3354734T3 (https=) |
| ES (1) | ES2801875T3 (https=) |
| HK (2) | HK1209781A1 (https=) |
| MX (1) | MX355408B (https=) |
| WO (1) | WO2013192576A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140004646A (ko) * | 2010-12-15 | 2014-01-13 | 미라젠 세러퓨틱스 | 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제 |
| HUE031595T2 (en) | 2011-04-25 | 2017-07-28 | Regulus Therapeutics Inc | Micro RNA Compounds s Methods for Modulating Mir-21 Activity |
| EA030211B1 (ru) | 2012-04-25 | 2018-07-31 | Регьюлэс Терапьютикс Инк. | Соединения на основе микрорнк и способы модулирования активности mir-21 |
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP2757157A1 (en) * | 2013-01-17 | 2014-07-23 | Ecole Polytechnique Federale de Lausanne (EPFL) | Modulation of mitophagy and use thereof |
| WO2014151835A1 (en) * | 2013-03-15 | 2014-09-25 | Miragen Therapeutics, Inc | Locked nucleic acid inhibitor of mir-145 and uses thereof |
| SG10201803157XA (en) | 2013-05-01 | 2018-05-30 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| CA2957618A1 (en) | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| KR20170033439A (ko) | 2014-08-07 | 2017-03-24 | 레굴루스 테라퓨틱스 인크 | 대사 장애에 대한 마이크로rna의 표적화 |
| WO2016069717A1 (en) * | 2014-10-28 | 2016-05-06 | MiRagen Therapeutics, Inc. | Inhibitors of mirnas in regulation of arterial stiffness and uses thereof |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| WO2017041020A1 (en) * | 2015-09-04 | 2017-03-09 | Oregon State University | Renal selective inhibition of cytochrome p450 3a5 |
| CN108025017A (zh) * | 2015-09-22 | 2018-05-11 | 米拉根医疗股份有限公司 | MiR-19调节剂及其用途 |
| CN108367021A (zh) * | 2015-10-15 | 2018-08-03 | 希望之城 | 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| EP3377073A4 (en) * | 2015-11-16 | 2019-06-26 | Ohio State Innovation Foundation | METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN |
| CN105435247A (zh) * | 2015-12-31 | 2016-03-30 | 中国医学科学院基础医学研究所 | miR-378在预防和/或治疗肥胖症中的用途 |
| WO2017187426A1 (en) * | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| CN106011140B (zh) * | 2016-06-06 | 2018-12-18 | 同济大学 | 反义microRNA-25及其应用 |
| WO2017214952A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 特异抑制人 miRNA-185 表达的慢病毒载体的构建及其应用 |
| WO2017214953A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种特异抑制人 miRNA-424 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219165A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异敲低人 miRNA-29a 和 miR-140 表达的慢病毒载体及其应用 |
| WO2017219166A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种同时抑制双 miRNA 表达的慢病毒载体及其应用 |
| WO2018009855A1 (en) * | 2016-07-07 | 2018-01-11 | MiRagen Therapeutics, Inc. | Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors |
| CN109891245B (zh) | 2016-08-12 | 2023-05-05 | 美国创新免疫科技有限公司 | 自身免疫疾病的诊断、预防和/或治疗 |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| WO2018183127A1 (en) * | 2017-03-25 | 2018-10-04 | MiRagen Therapeutics, Inc. | Mir-92 inhibitors for treatment of heart failure |
| CN110141577A (zh) * | 2018-02-13 | 2019-08-20 | 上海三炬生物科技有限公司 | miRNA-24-3p核苷酸类似物在制备药物中的应用 |
| KR20200131287A (ko) * | 2018-03-14 | 2020-11-23 | 베스 이스라엘 데코니스 메디칼 센터 | 마이크로-rna 22의 억제제 |
| US12005120B2 (en) | 2018-05-08 | 2024-06-11 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect |
| WO2020051398A1 (en) * | 2018-09-06 | 2020-03-12 | Aptamir Therapeutics, Inc. | Metabolic benefits of short mir-22 mirna antagomir therapies |
| CN110358769A (zh) * | 2019-07-30 | 2019-10-22 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 经锁核酸和硫代磷酸修饰的miRNA类似物及其在制备抗肿瘤药物中的应用 |
| CN110433170B (zh) * | 2019-07-31 | 2021-04-27 | 南京医科大学 | 心脏抽吸液miR-28-5p在心脏疾病中的应用 |
| IT201900017234A1 (it) * | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA per il trattamento del leiomioma |
| US20220395587A1 (en) * | 2019-11-15 | 2022-12-15 | Duke University | Cellular molecular theranostics nanoprobe systems and methods |
| CN111118008B (zh) * | 2020-01-16 | 2023-08-22 | 南京医科大学 | Mcl1基因的3’-UTR序列及其应用 |
| WO2021178344A1 (en) * | 2020-03-04 | 2021-09-10 | The Trustees Of Indiana University | Methods to re-engage a fetal wound healing pathway for adult skin repair |
| WO2022018269A1 (en) * | 2020-07-23 | 2022-01-27 | Johann Wolfgang Goethe-Universität Frankfurt | Combinatorial inhibition of mirnas for treatment of heart failure |
| CN116801916A (zh) * | 2021-01-18 | 2023-09-22 | 礼赞伊诺制药株式会社 | 包含miR 145抑制剂作为有效成分的用于治疗心肌梗塞的组合物 |
| CN120584186A (zh) | 2023-02-07 | 2025-09-02 | 特罗姆瑟大学-挪威北极圈大学 | 用于在静脉血栓栓塞的治疗中使用的药物组合物 |
| GB202305535D0 (en) | 2023-04-14 | 2023-05-31 | Imperial College Innovations Ltd | Oligonucleotide decoy |
| WO2025008641A2 (en) * | 2023-07-06 | 2025-01-09 | Imperial College Innovations Limited | Rna molecule |
| WO2025104709A1 (en) * | 2023-11-17 | 2025-05-22 | Biorchestra Co., Ltd. | Microrna-378a-3p antisense oligonucleotides and uses thereof |
| CN121204147A (zh) * | 2024-06-24 | 2025-12-26 | 中山大学 | 靶向rna修饰调控的方法 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| JP2002516256A (ja) | 1998-05-26 | 2002-06-04 | アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド | 二環式糖成分を有する新規ヌクレオシド |
| HK1048339A1 (zh) | 1999-03-18 | 2003-03-28 | 埃克西库恩公司 | 利用特异性lna引物检测基因突变 |
| AU7406600A (en) * | 1999-10-04 | 2001-05-10 | Exiqon A/S | A method of increasing the specificity of oxy-lna oligonucleotides |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| GB2424887B (en) | 2003-11-26 | 2008-05-21 | Univ Massachusetts | Sequence-specific inhibition of small RNA function |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| EP1723162A4 (en) | 2004-02-13 | 2010-05-05 | Univ Rockefeller | ANTI-microRNA oligonucleotide molecules |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| US20060148742A1 (en) | 2004-02-26 | 2006-07-06 | Kaye David M | Polynucleotide delivery to cardiac tissue |
| WO2005082440A1 (en) | 2004-02-26 | 2005-09-09 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| EP2290073A3 (en) | 2004-05-28 | 2011-08-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2302055B1 (en) | 2004-11-12 | 2014-08-27 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| CN101203611B (zh) | 2005-04-19 | 2013-08-14 | 巴斯福植物科学有限公司 | 控制基因表达的改良方法 |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| KR101485071B1 (ko) | 2005-12-12 | 2015-01-26 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 마이크로 ｒｎａ를 이용한 근육 세포 증식 및 분화 조절방법과 근육 세포 치료방법 및 유전자 발현 억제방법그리고 마이크로 ｒｎａ 분자의 발현용 벡터와 이를 이용한키트 및 미오사이트 |
| WO2007073737A1 (en) | 2005-12-29 | 2007-07-05 | Exiqon A/S | Detection of tissue origin of cancer |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| EP2007888A2 (en) * | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| WO2008014008A2 (en) | 2006-07-28 | 2008-01-31 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| AU2007281261B2 (en) | 2006-08-01 | 2013-03-21 | Board Of Regents Of The University Of Texas System | Identification of a micro-RNA that activates expression of beta-myosin heavy chain |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| EP2208798B1 (de) | 2006-10-09 | 2013-08-07 | Medizinische Hochschule Hannover | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
| WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| MX2009006310A (es) | 2006-12-14 | 2009-07-22 | Novartis Ag | Composiciones y metodos para tratar trastornos musculares y cardiovasculares. |
| WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| WO2008131191A2 (en) | 2007-04-20 | 2008-10-30 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
| EP2187896B1 (en) | 2007-07-31 | 2016-01-13 | The Board of Regents of The University of Texas System | Inhibitors of mir-499 and mir-208b for use in the treatment of pathologic cardiac hypertrophy, heart failure or myocardial infarction |
| US20100292099A1 (en) | 2007-08-23 | 2010-11-18 | Keren Pharmaceutical, Inc. | Targeting of rna with external guide sequences |
| EP2610342B1 (en) | 2007-09-14 | 2016-05-04 | The Ohio State University Research Foundation | MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof |
| EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| CN101424640B (zh) | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
| KR20100099158A (ko) | 2007-11-09 | 2010-09-10 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ |
| US8404658B2 (en) | 2007-12-31 | 2013-03-26 | Nanocor Therapeutics, Inc. | RNA interference for the treatment of heart failure |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| WO2009114681A2 (en) | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| US8222221B2 (en) | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
| WO2009151600A2 (en) | 2008-06-10 | 2009-12-17 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US20110172292A1 (en) * | 2008-06-30 | 2011-07-14 | Hansen Jens Bo Rode | Antidote oligomers |
| CN101386848A (zh) | 2008-08-12 | 2009-03-18 | 南京大学 | 细胞微粒子所载微小核糖核酸及其制备研究方法和应用 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| RU2515926C2 (ru) | 2009-02-04 | 2014-05-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца |
| ES2599979T3 (es) * | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
| WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| SG176716A1 (en) | 2009-06-08 | 2012-01-30 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
| AU2010294197C9 (en) | 2009-09-10 | 2018-09-13 | Velin-Pharma A/S | Method for the preparation of micro-RNA and its therapeutic application |
| EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| US8592151B2 (en) | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
| US20130109738A1 (en) | 2010-02-24 | 2013-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Control of Cardiac Growth, Differentiation and Hypertrophy |
| WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| EP2559442B1 (en) | 2010-04-13 | 2017-12-06 | Jiangsu Mingma Biotech Co., Ltd | Method for regulating microrna content in organisms and uses thereof |
| EP2561091B1 (en) | 2010-04-20 | 2014-08-06 | Comprehensive Biomarker Center GmbH | Complex mirna sets as novel biomarkers for an acute coronary syndrome |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US20130150256A1 (en) | 2010-06-11 | 2013-06-13 | Jane Synnergren | Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types |
| ITMI20101089A1 (it) | 2010-06-16 | 2011-12-17 | Istituto Naz Di Genetica Molecolare Ingm | Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario |
| CA2804791C (en) | 2010-07-08 | 2019-07-30 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
| GB201012418D0 (en) * | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
| US20130137753A1 (en) | 2010-08-03 | 2013-05-30 | University Of South Alabama | Methods and compositions for the diagnosis and treatment of breast cancer |
| WO2012020308A2 (en) | 2010-08-13 | 2012-02-16 | The University Court Of The University Of Glasgow | Cellular and molecular therapies |
| US9243246B2 (en) | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
| CA2812046A1 (en) * | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2012061810A1 (en) | 2010-11-05 | 2012-05-10 | Miragen Therapeutics | Base modified oligonucleotides |
| KR20140004646A (ko) * | 2010-12-15 | 2014-01-13 | 미라젠 세러퓨틱스 | 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제 |
| WO2012149646A1 (en) | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| KR20140091688A (ko) | 2011-10-06 | 2014-07-22 | 미라젠 세러퓨틱스 인코포레이티드 | 마이크로rna 조절에 의한 전신 에너지 항상성의 제어 |
| GB201117482D0 (en) | 2011-10-11 | 2011-11-23 | Univ Dundee | Targetiing of miRNA precursors |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| CN107266391B (zh) | 2011-10-18 | 2020-04-17 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| EP2816114A3 (en) | 2011-12-15 | 2015-02-25 | Oncostamen S.r.l. | MicroRNAs and uses thereof |
| EP2604690A1 (en) | 2011-12-15 | 2013-06-19 | Oncostamen S.r.l. | MicroRNAs and uses thereof |
| FR2984358A1 (fr) | 2011-12-16 | 2013-06-21 | Genethon | Methodes pour le diagnostic de dystrophies musculaires |
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| ES2606636T3 (es) | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
-
2013
- 2013-06-21 CN CN201710249089.9A patent/CN107236735B/zh not_active Expired - Fee Related
- 2013-06-21 KR KR1020157000512A patent/KR101928418B1/ko not_active Expired - Fee Related
- 2013-06-21 CA CA2876180A patent/CA2876180C/en not_active Expired - Fee Related
- 2013-06-21 JP JP2015518626A patent/JP6208228B2/ja not_active Expired - Fee Related
- 2013-06-21 EP EP13807536.1A patent/EP2864482A4/en not_active Withdrawn
- 2013-06-21 AU AU2013278011A patent/AU2013278011B2/en not_active Ceased
- 2013-06-21 DK DK18154472.7T patent/DK3354734T3/da active
- 2013-06-21 ES ES18154472T patent/ES2801875T3/es active Active
- 2013-06-21 WO PCT/US2013/047157 patent/WO2013192576A2/en not_active Ceased
- 2013-06-21 CN CN201380038840.0A patent/CN104685056A/zh active Pending
- 2013-06-21 US US13/924,340 patent/US9388408B2/en not_active Expired - Fee Related
- 2013-06-21 HK HK15110337.4A patent/HK1209781A1/xx unknown
- 2013-06-21 MX MX2014015643A patent/MX355408B/es active IP Right Grant
- 2013-06-21 EP EP18154472.7A patent/EP3354734B1/en active Active
-
2016
- 2016-05-13 US US15/154,711 patent/US9803202B2/en not_active Expired - Fee Related
-
2017
- 2017-09-06 JP JP2017171211A patent/JP2017217007A/ja active Pending
- 2017-09-13 US US15/703,753 patent/US10337005B2/en not_active Expired - Fee Related
-
2018
- 2018-03-22 HK HK18103977.1A patent/HK1244509A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9388408B2 (en) | 2016-07-12 |
| DK3354734T3 (da) | 2020-06-29 |
| EP2864482A4 (en) | 2016-02-10 |
| EP2864482A2 (en) | 2015-04-29 |
| US20180273944A1 (en) | 2018-09-27 |
| JP2015521626A (ja) | 2015-07-30 |
| MX2014015643A (es) | 2015-07-17 |
| AU2013278011A1 (en) | 2015-01-15 |
| EP3354734B1 (en) | 2020-06-10 |
| JP2017217007A (ja) | 2017-12-14 |
| HK1244509A1 (zh) | 2018-08-10 |
| WO2013192576A3 (en) | 2014-04-03 |
| JP6208228B2 (ja) | 2017-10-04 |
| CA2876180C (en) | 2019-11-19 |
| US20160326526A1 (en) | 2016-11-10 |
| KR101928418B1 (ko) | 2018-12-12 |
| WO2013192576A2 (en) | 2013-12-27 |
| CN104685056A (zh) | 2015-06-03 |
| KR20150023687A (ko) | 2015-03-05 |
| US9803202B2 (en) | 2017-10-31 |
| EP3354734A1 (en) | 2018-08-01 |
| CN107236735A (zh) | 2017-10-10 |
| ES2801875T3 (es) | 2021-01-14 |
| AU2013278011B2 (en) | 2018-09-20 |
| US10337005B2 (en) | 2019-07-02 |
| US20130344135A1 (en) | 2013-12-26 |
| CN107236735B (zh) | 2019-11-08 |
| CA2876180A1 (en) | 2013-12-27 |
| HK1209781A1 (en) | 2016-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355408B (es) | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. | |
| MX2013014378A (es) | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| MX2013009191A (es) | Oligonucleotidos antisentido. | |
| MD20150006A2 (ro) | Inhibitori de micro-ARN din familia miR-15 | |
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| EA200870402A1 (ru) | Фармацевтическая композиция | |
| WO2014154835A3 (en) | Modified tgf-beta oligonucleotides | |
| EA201100811A1 (ru) | Фармацевтическая композиция | |
| WO2009014887A3 (en) | Stabilized immune modulatory rna (simra) compounds | |
| NZ592867A (en) | Compositions and methods for inhibiting expression of transthyretin | |
| MX2010004452A (es) | Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico. | |
| MX359548B (es) | Agentes de iarn modificados. | |
| MX2011013176A (es) | Motivos de modificación química para inhibidores y miméticos del miarn. | |
| WO2009111658A3 (en) | Compositions and methods for inhibiting expression of eg5 and vegf genes | |
| WO2011008730A3 (en) | Chemical modification of small hairpin rnas for inhibition of gene expression | |
| IN2014CN03921A (https=) | ||
| WO2010003420A3 (en) | Treatment of psoriasis and related diseases by mirna modulation | |
| HK1199285A1 (en) | Compositions and methods for inducing apoptosis | |
| WO2011054939A3 (en) | Compositions and methods for inhibiting expression of kif10 genes | |
| WO2011065677A3 (ko) | 암 치료용 약학 조성물 | |
| NZ728207A (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |